FDA Approves Brain Penetrant Therapy for Gaucher Type 3

Company Sanofi (Genzyme) Event Type FDA approval (previously missed 18 Nov action) Modality Oral glucosylceramide synthase inhibitor Asset Venglustat (Infilbray) Target Glucosylceramide synthase Disease Area Neurological symptoms of Gaucher disease type 3 Summary FDA approved venglustat, Infilbray, on November 18 for neurological symptoms of Gaucher…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *